Background: Multidrug-resistant (MDR) enterococci have become a major problem in recent times and have been reported increasingly around the world. Lytic phages infect bacteria leading to rapid host death with limited risk of phage transduction, underlining the increasing interest in potential phage therapy in the future. Objective (s): The aim of this study is to use phage therapy as alternative approach for treatment of Enterococcus faecalis infections that recorded as MDR in Iraq to tackle this problem. Materials and Methods: Thirty E. faecalis isolates were collected from patients with different infectious diseases such as urinary tract infection (UTI), diabetic foot, septicemia, and wound infections. The isolation of specific lytic phages was from different environmental sources such as (sewage, and wastewater). The biokinetic assays were carried out to measure the characteristics of the isolated phage. The study of the bacteriophage and the formed phage cocktail infectivity against isolates E.faecalis was tested by the top layer assay. The phage endolysin was extracted from the best bacteriophage that gave best results. Results: All the isolated E.faecalis was reported as MDR in this study. About 75 E.faecalis specific phages were isolated and purified. All the isolated bacteria were 100% sensitive to the lytic phages. The formed phage cocktail was capable to create inhibition zones on the most bacterial isolates' lawns. The molecular weight and the concentration of the extracted endolysin was evaluated in this study and found to be as (48 kDa) and (0.5mg/ml), respectively. The antibacterial activity of the extracted endolysin was evaluated by the turbidity reduction assay. A clear decline in the bacterial growth was manifested (5x107 CFU/ml) to (1x104 CFU/ml), in which the bacterial growth was reduced by (3.63 log). The endolysin found to be effective against 90% of E.faeclais isolates. Conclusion: The activity of the isolated specific phage together with the activity of the formed phage cocktail, were efficient as successful and inexpensive method of therapy against MDR E.faecalis. The potential of the extracted endolysin over the phage therapy was verified in this study. The coverage rate and the absence of resistant E.faecalis to the phage and its endolysin had emphasized on the importance of this alternative therapy to commonly used antibiotics. List of abbreviation: MDR = multiple drug-resistant, E. faecalis = Enterococcus faecalis, BT = burst time, BS = burst size, IP = infective percentage, Phage =bacteriophage, CFU = Colony forming unit, kDa = Kilodalton, OD = Optical Densities.
Cite this article:
Shaymaa Husham Ahmed, Rand R. Hafidh. The Isolation of specifically lytic phages along with their extracted endolysins as antibacterial agents to MDR Enterococcus faecalis. Research Journal of Pharmacy and Technology. 2021; 14(9):4547-4. doi: 10.52711/0974-360X.2021.00791
Shaymaa Husham Ahmed, Rand R. Hafidh. The Isolation of specifically lytic phages along with their extracted endolysins as antibacterial agents to MDR Enterococcus faecalis. Research Journal of Pharmacy and Technology. 2021; 14(9):4547-4. doi: 10.52711/0974-360X.2021.00791 Available on: https://rjptonline.org/AbstractView.aspx?PID=2021-14-9-5
1. Takahashi, Yukina, Tatsuma, Tetsu. Metal oxides and hydroxides as rechargeable materials for photocatalysts with oxidative energy storage abilities. Electrochemistry. 2014; 82(9): 749-751.
2. Sreeja MK, Gowrishankar NL, Adisha S, Divya KC. Antibiotic resistance-reasons and the most common resistant pathogens – A review. Res J Pharm Technol. 2017; 10(6): 1886-1890.
3. Kim Y Bin, Seo KW, Shim JB, Son S hyun, Noh EB, Lee YJ. Molecular characterization of antimicrobial-resistant Enterococcus faecalis and Enterococcus faecium isolated from layer parent stock. Poult Sci. 2019; 98(11): 5892-5899.
4. Ramsey, Matthew, Hartke, Axel, Huycke, Mark. The Physiology and Metabolism of Enterococci. Enterococci From Commensals to Lead Causes Drug Resist Infect. 2014: 1-55.
5. Lebreton, Francois, Willems, L. RJ, Gilmore, S. M. Enterococcus Diversity, Origins in Nature, and Gut Colonization. Enterococci From Commensals to Lead Causes Drug Resist Infect. 2014: 1-59.
6. Padavala Sisira, Gopinath P. Detection of Esp gene for the presence of extracellular surface protein among clinical isolates of enterococcus species. Res J Pharm Technol. 2017; 10(5): 1370-1372.
7. Das Tandra T., Gopinath P. Biofilm formation among enterococci species. Res J Pharm Technol. 2016; 9(11): 1877-1879.
8. Sheik Ruksana, Gopinath P. Detection of vancomycin resistance among clinical isolates of enterococci. Res J Pharm Technol. 2016; 9(12): 2106.
9. Vyas, Ashish, Singh, Karamjeet, Kumar, Gaurav. Prevalence and drug resistance among bacteria of urinary tract infections in females in Punjab, India. Res J Pharm Technol. 2017; 10(2): 575.
10. Nandakumar E., Gopinath P. Detection of gelatinase and haemolysin among clinical isolates of enterococci. Res J Pharm Technol. 2016; 9(9): 1393-1396.
11. Deeban Ananda K.B.S., Gopinath P. Detection of High Level Aminoglycoside Resistance (HLAR) among clinical isolates of Enterococci. Res J Pharm Technol. 2017; 10(12): 4195. 12. Divya G, Elango P, Padmaraj R, Srivani Ramesh S. Molecular characterization of macrolide resistance genes among the clinical isolates of enterococci. Res J Pharm Technol. 2017; 10(7): 2018-2022.
12. Divya G, Elango P, Padmaraj R, Srivani Ramesh S. Molecular characterization of macrolide resistance genes among the clinical isolates of enterococci. Res J Pharm Technol. 2017; 10(7): 2018-2022.
13. Karthik A., Gopinath P. Antibacterial activity of apple cider vinegar against clinical isolates of enterococcus Spp. Res J Pharm Technol. 2018; 11(8): 3259-3262. 14. Bokadia Sneha G., Gopinath P. Bacteriophage in Human Body A-Systematic Review. Res J Pharm Technol. 2017; 10(4): 1204.
14. Bokadia Sneha G., Gopinath P. Bacteriophage in Human Body A-Systematic Review. Res J Pharm Technol. 2017; 10(4): 1204.
15. Sweere JM, Van Belleghem JD, Ishak H, et al. Bacteriophage trigger antiviral immunity and prevent clearance of bacterial infection. Science (80- ). 2019; 363(6434): 9203.
16. Lossouarn J, Briet A, Moncaut E, et al. Enterococcus faecalis countermeasures defeat a virulent picovirinae bacteriophage. Viruses. 2019; 11(1).
17. Fernández L, Gutiérrez D, García P, Rodríguez A. The perfect bacteriophage for therapeutic applications—A quick guide. Antibiotics. 2019; 8(3): 2020.
18. Heler R, Samai P, Modell JW, et al. Cas9 specifies functional viral targets during CRISPR-Cas adaptation. Nature. 2015; 519(7542): 199-202.
19. Oechslin F. Resistance Development to Bacteriophages Occurring during Bacteriophage Therapy. Viruses. 2018; 10: 351.
20. Wagemans J, Blasdel BG, Van den Bossche A, et al. Functional elucidation of antibacterial phage ORFans targeting Pseudomonas aeruginosa. Cell Microbiol. 2014; 16(12): 1822-1835.
21. Domingo-Calap, Pilar, Georgel, Philippe, Bahram, Seiamak. Back to the future: Bacteriophages as promising therapeutic tools. Hla. 2016; 87(3): 133-140.
22. Kakasis, Athanasios, Panitsa, Gerasimia. Bacteriophage therapy as an alternative treatment for human infections. A comprehensive review. Int J Antimicrob Agents. 2019; 53(1): 16-21.
23. Zuo T, Wong SH, Lam K, et al. Bacteriophage transfer during faecal microbiota transplantation in Clostridium dif fi cile infection is associated with treatment outcome. Gut. 2018; 67: 634-643.
24. Barr JJ. A bacteriophages journey through the human body. Immunol Rev. 2017; 279: 106-122.
25. Loessner, J. M, Maier, et al. Three Bacillus cereus bacteriophage endolysins are unrelated but reveal high homology to cell wall hydrolases from different bacilli. J Bacteriol. 1997; 179(9): 2845-2851.
26. Gupta, Ragini, Prasad, Yogendra. P-27/HP endolysin as antibacterial agent for antibiotic resistant Staphylococcus aureus of human infections. Curr Microbiol. 2011; 63(1): 39-45.
27. Schmelcher, Mathias, Donovan, M. D, Loessner, Martin J. Bacteriophage endolysins as novel antimicrobials. Future Microbiol. 2012; 7(10): 1147-1171.
28. Ali R M, Abdulamir S A, Kadhim R S. Extraction, purification and therapeutic use of bacteriophage endolysin against multi-drug resistant Staphylococcus aureus: In vivo and in vitro study. J Contemp Med Sci. 2018; 4: 33-38.
29. Jasim, N., Hayder, Abdul-Ameer, S. A. Phage Cocktails Against Highly Multi-Drug Resistant Acinetobacter baumanii. Iraqi JMS. 2018; 16(4)(3): 357-371.
30. García-Solache, Mónica, Rice, B. L. The enterococcus: A model of adaptability to its environment. Clin Microbiol Rev. 2019; 32(2): 1-28.
31. Bolocan S.Andrei, Upadrasta Aditya, Bettio Almeida PH De. Evaluation of Phage Therapy in the Context of Enterococcus faecalis and Its Associated Diseases. Multidiscip Digit Publ Inst. 2019; 11(4): 366.
32. Kadhem, S H, Flayyih, T M. Isolation and Identification of Vancomycin-Resistant Enterococcus Faecalis. Iraqi J Sci. 2014; 55(4): 1811-1816.
33. Salem-bekhit MM, Mohamed I, Moussa I, Mahmoud MMM. Increasing prevalence of high-level gentamicin resistant enterococci: An emerging clinical problem. African J Microbiol Res. 2011; 5(31): 5713-5720.
34. Luna Adhikari. High-level Aminoglycoside Resistance and Reduced Susceptibility to Vancomycin in Nosocomial Enterococci National Center for Biotechnology Information. J Glob Infect Dis. 2010; 2(3): 231-235.
35. Flores-mireles AL, Walker JN, Caparon M, Hultgren SJ. and treatment options. 2016; 13(5): 269-284.
36. Tellis R, S M. a Prospective Study of Antibiotic Resistance and Virulence Factors in Enterococci Isolated from Patients with End Stage Renal Disease. Int J Biomed Res. 2012; 3(3): 2020.
37. Ahmed A. Al-naqshbandi, Chawsheen M. Prevalence and antimicrobial susceptibility of bacterial pathogens isolated from urine specimens received in rizgary hospital — Erbil. J Infect Public Health. 2020; 12(3): 330-336.
38. Alshammari, Fawaz, Alam, et al. Antimicrobial Resistant Enterococcus sp . Isolated from Clinical Samples. J Pharm Res Int. 2020;32(11): 93-101.
39. Esmail Monem Abdel M, Abdulghany M Hend, Khairy MM R. Prevalence of Multidrug-Resistant Enterococcus faecalis in Hospital-Acquired Surgical Wound Infections and Bacteremia: Concomitant Analysis of Antimicrobial Resistance Genes. Infect Dis Res Treat. 2019; 12: 117863371988292.
40. Bertelloni F, Salvadori C, Moni A, Cerri D, Mani P, Ebani VV. Antimicrobial resistance in Enterococcus spp . isolated from laying hens of backyard poultry flocks. Ann Agric Environ Med. 2015; 22(4): 665-669.
41. Al-Zubidi M, Widziolek M, Court EK, et al. Identification of novel bacteriophages with therapeutic potential that target enterococcus faecalis. Infect Immun. 2019; 87(11): 1-19. 42. Zhang, Hongming, Buttaro, A B. Bacteriophage _Ef11 ORF28 Endolysin, a Multifunctional Lytic Enzyme with Properties Distinct from All Other Identified Enterococcus faecalis Phage Endolysins. Appl Environ Microbiol. 2019; 85(13): 1-22.
42. Zhang, Hongming, Buttaro, A B. Bacteriophage _Ef11 ORF28 Endolysin, a Multifunctional Lytic Enzyme with Properties Distinct from All Other Identified Enterococcus faecalis Phage Endolysins. Appl Environ Microbiol. 2019; 85(13): 1-22.
43. Swift SM, Rowley DT, Young C, Franks A, Hyman P, Donovan DM. The endolysin from the Enterococcus faecalis bacteriophage VD13 and conditions stimulating its lytic activity. 2016; (September): 1-8.
44. Cheng M, Zhang Y, Li X, et al. Endolysin LysEF-P10 shows potential as an alternative treatment strategy for multidrug-resistant Enterococcus faecalis infections. Sci Rep. 2017; 7(1): 1-15.